Can diabetes drugs fix Post-Transplant metabolism? new trial investigates
NCT ID NCT05013112
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether two diabetes drugs, metformin and empagliflozin, can safely improve metabolic problems (like unhealthy fat buildup and blood sugar issues) in people who have had a kidney transplant. 105 kidney transplant recipients with good kidney function were randomly assigned to one of three groups: metformin, empagliflozin, or standard care. The main goal was to see if these drugs could reduce the ratio of visceral (belly) fat to subcutaneous fat over 12 months, which is a marker of heart disease risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EMPAGLIFLOZIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West china hospital
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients
- New Two-Step therapy aims to stop chronic kidney transplant rejection
- Smartphone app and booklet could help kidney transplant patients stick to medications